Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
Background: Atezolizumab plus bevacizumab was approved for patients with hepatocellular carcinoma (HCC). Although clinical trials have revealed its efficacy, the outcomes in the real-world clinical practice are unclear. We retrospectively evaluated the efficacy and safety of atezolizumab plus bevaci...
Gespeichert in:
| Veröffentlicht in: | Cancers 2021-06, Vol.13 (11), p.2786 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 11 |
| container_start_page | 2786 |
| container_title | Cancers |
| container_volume | 13 |
| creator | Iwamoto, Hideki Shimose, Shigeo Noda, Yu Shirono, Tomotake Niizeki, Takashi Nakano, Masahito Okamura, Shusuke Kamachi, Naoki Suzuki, Hiroyuki Sakai, Miwa Kajiwara, Akira Itano, Satoshi Tanaka, Masatoshi Yamaguchi, Taizo Kuromatsu, Ryoko Koga, Hironori Torimura, Takuji |
| description | Background: Atezolizumab plus bevacizumab was approved for patients with hepatocellular carcinoma (HCC). Although clinical trials have revealed its efficacy, the outcomes in the real-world clinical practice are unclear. We retrospectively evaluated the efficacy and safety of atezolizumab plus bevacizumab for HCC. Materials and Methods: This is a multicenter study conducted between November 2020 and March 2021. Among the 61 patients, 51 were assessed for progression-free survival (PFS), therapeutic response, and adverse events (AEs). Results: The median PFS was 5.4 months. The objective response rate (ORR) was 35.3%. The disease control rate (DCR) was 86.3%. The incidence rates of AEs at any grade and grade >3 were 98.0% and 29.4%, respectively. The most frequent AE at any grade and grade >3 was hepatic disorder. In patients with a previous history of molecular targeted agent (MTA) or the degree of albumin-bilirubin (ALBI) grade, there were no significant differences in the PFS, ORR, DCR, and incidence rates of AEs. Conclusion: The study demonstrated that atezolizumab plus bevacizumab was effective and safe for patients with HCC even in the real-world setting including patients with a previous MTA history or other than ALBI grade 1. |
| doi_str_mv | 10.3390/cancers13112786 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8199943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2539606086</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-69efd41ba3713a3c5ab7493f5ea71cd31dc43faaaa3b8a9ca3c46c817d8717d3</originalsourceid><addsrcrecordid>eNpdkUFr3TAMx83YWMtbz7sadtklqx05TnwZdI-uLRRWRseOQXGUzcWx3-ykdIV997r0MbbqYAnpx1-SxdhbKT4AGHFsMVhKWYKUddvpF-ywFm1daW3Uy3_iA3aU840oBiBb3b5mB6Bq0QhjDtmfi-AWh56f3u0oOSqKPE78ZKH76N39OuPAr_ya-Se6RbtPTDHxbyFRJrvg4Imf0w6XaMn71WPiW0zWhTgjd4F_JfTV95j8yLfeBWdLs6uEdnGW3rBXE_pMR3u_YdefT6-359Xll7OL7cllZZVWS6UNTaOSA0IrAcE2OLTKwNQQttKOIEerYMJiMHRobEGUtp1sx64tD2zYxyfZ3TrMNFoKS0Lf75KbMf3uI7r-_0pwP_sf8bbvpDFGQRF4vxdI8ddKeelnlx_XxUBxzX3dqA5MA-WLN-zdM_QmrimU7QoFRgstOl2o4yfKpphzounvMFL0j8ftnx0XHgDwGJq6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2539606086</pqid></control><display><type>article</type><title>Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Iwamoto, Hideki ; Shimose, Shigeo ; Noda, Yu ; Shirono, Tomotake ; Niizeki, Takashi ; Nakano, Masahito ; Okamura, Shusuke ; Kamachi, Naoki ; Suzuki, Hiroyuki ; Sakai, Miwa ; Kajiwara, Akira ; Itano, Satoshi ; Tanaka, Masatoshi ; Yamaguchi, Taizo ; Kuromatsu, Ryoko ; Koga, Hironori ; Torimura, Takuji</creator><creatorcontrib>Iwamoto, Hideki ; Shimose, Shigeo ; Noda, Yu ; Shirono, Tomotake ; Niizeki, Takashi ; Nakano, Masahito ; Okamura, Shusuke ; Kamachi, Naoki ; Suzuki, Hiroyuki ; Sakai, Miwa ; Kajiwara, Akira ; Itano, Satoshi ; Tanaka, Masatoshi ; Yamaguchi, Taizo ; Kuromatsu, Ryoko ; Koga, Hironori ; Torimura, Takuji ; on behalf of The Kurume Liver Cancer Study Group of Japan</creatorcontrib><description>Background: Atezolizumab plus bevacizumab was approved for patients with hepatocellular carcinoma (HCC). Although clinical trials have revealed its efficacy, the outcomes in the real-world clinical practice are unclear. We retrospectively evaluated the efficacy and safety of atezolizumab plus bevacizumab for HCC. Materials and Methods: This is a multicenter study conducted between November 2020 and March 2021. Among the 61 patients, 51 were assessed for progression-free survival (PFS), therapeutic response, and adverse events (AEs). Results: The median PFS was 5.4 months. The objective response rate (ORR) was 35.3%. The disease control rate (DCR) was 86.3%. The incidence rates of AEs at any grade and grade >3 were 98.0% and 29.4%, respectively. The most frequent AE at any grade and grade >3 was hepatic disorder. In patients with a previous history of molecular targeted agent (MTA) or the degree of albumin-bilirubin (ALBI) grade, there were no significant differences in the PFS, ORR, DCR, and incidence rates of AEs. Conclusion: The study demonstrated that atezolizumab plus bevacizumab was effective and safe for patients with HCC even in the real-world setting including patients with a previous MTA history or other than ALBI grade 1.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13112786</identifier><identifier>PMID: 34205099</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Adverse events ; Bevacizumab ; Bilirubin ; Cancer therapies ; Clinical medicine ; Clinical trials ; Disease control ; Hepatocellular carcinoma ; Hypertension ; Liver cancer ; Magnetic resonance imaging ; Monoclonal antibodies ; Patients ; Pharmaceuticals ; Response rates ; Statistical analysis ; Tumors ; Variance analysis</subject><ispartof>Cancers, 2021-06, Vol.13 (11), p.2786</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-69efd41ba3713a3c5ab7493f5ea71cd31dc43faaaa3b8a9ca3c46c817d8717d3</citedby><cites>FETCH-LOGICAL-c464t-69efd41ba3713a3c5ab7493f5ea71cd31dc43faaaa3b8a9ca3c46c817d8717d3</cites><orcidid>0000-0002-3375-180X ; 0000-0002-4791-8885 ; 0000-0001-5814-9543 ; 0000-0002-2662-6779 ; 0000-0003-2068-8386 ; 0000-0003-2383-5038</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199943/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199943/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Iwamoto, Hideki</creatorcontrib><creatorcontrib>Shimose, Shigeo</creatorcontrib><creatorcontrib>Noda, Yu</creatorcontrib><creatorcontrib>Shirono, Tomotake</creatorcontrib><creatorcontrib>Niizeki, Takashi</creatorcontrib><creatorcontrib>Nakano, Masahito</creatorcontrib><creatorcontrib>Okamura, Shusuke</creatorcontrib><creatorcontrib>Kamachi, Naoki</creatorcontrib><creatorcontrib>Suzuki, Hiroyuki</creatorcontrib><creatorcontrib>Sakai, Miwa</creatorcontrib><creatorcontrib>Kajiwara, Akira</creatorcontrib><creatorcontrib>Itano, Satoshi</creatorcontrib><creatorcontrib>Tanaka, Masatoshi</creatorcontrib><creatorcontrib>Yamaguchi, Taizo</creatorcontrib><creatorcontrib>Kuromatsu, Ryoko</creatorcontrib><creatorcontrib>Koga, Hironori</creatorcontrib><creatorcontrib>Torimura, Takuji</creatorcontrib><creatorcontrib>on behalf of The Kurume Liver Cancer Study Group of Japan</creatorcontrib><title>Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice</title><title>Cancers</title><description>Background: Atezolizumab plus bevacizumab was approved for patients with hepatocellular carcinoma (HCC). Although clinical trials have revealed its efficacy, the outcomes in the real-world clinical practice are unclear. We retrospectively evaluated the efficacy and safety of atezolizumab plus bevacizumab for HCC. Materials and Methods: This is a multicenter study conducted between November 2020 and March 2021. Among the 61 patients, 51 were assessed for progression-free survival (PFS), therapeutic response, and adverse events (AEs). Results: The median PFS was 5.4 months. The objective response rate (ORR) was 35.3%. The disease control rate (DCR) was 86.3%. The incidence rates of AEs at any grade and grade >3 were 98.0% and 29.4%, respectively. The most frequent AE at any grade and grade >3 was hepatic disorder. In patients with a previous history of molecular targeted agent (MTA) or the degree of albumin-bilirubin (ALBI) grade, there were no significant differences in the PFS, ORR, DCR, and incidence rates of AEs. Conclusion: The study demonstrated that atezolizumab plus bevacizumab was effective and safe for patients with HCC even in the real-world setting including patients with a previous MTA history or other than ALBI grade 1.</description><subject>Adverse events</subject><subject>Bevacizumab</subject><subject>Bilirubin</subject><subject>Cancer therapies</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Disease control</subject><subject>Hepatocellular carcinoma</subject><subject>Hypertension</subject><subject>Liver cancer</subject><subject>Magnetic resonance imaging</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>Pharmaceuticals</subject><subject>Response rates</subject><subject>Statistical analysis</subject><subject>Tumors</subject><subject>Variance analysis</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkUFr3TAMx83YWMtbz7sadtklqx05TnwZdI-uLRRWRseOQXGUzcWx3-ykdIV997r0MbbqYAnpx1-SxdhbKT4AGHFsMVhKWYKUddvpF-ywFm1daW3Uy3_iA3aU840oBiBb3b5mB6Bq0QhjDtmfi-AWh56f3u0oOSqKPE78ZKH76N39OuPAr_ya-Se6RbtPTDHxbyFRJrvg4Imf0w6XaMn71WPiW0zWhTgjd4F_JfTV95j8yLfeBWdLs6uEdnGW3rBXE_pMR3u_YdefT6-359Xll7OL7cllZZVWS6UNTaOSA0IrAcE2OLTKwNQQttKOIEerYMJiMHRobEGUtp1sx64tD2zYxyfZ3TrMNFoKS0Lf75KbMf3uI7r-_0pwP_sf8bbvpDFGQRF4vxdI8ddKeelnlx_XxUBxzX3dqA5MA-WLN-zdM_QmrimU7QoFRgstOl2o4yfKpphzounvMFL0j8ftnx0XHgDwGJq6</recordid><startdate>20210603</startdate><enddate>20210603</enddate><creator>Iwamoto, Hideki</creator><creator>Shimose, Shigeo</creator><creator>Noda, Yu</creator><creator>Shirono, Tomotake</creator><creator>Niizeki, Takashi</creator><creator>Nakano, Masahito</creator><creator>Okamura, Shusuke</creator><creator>Kamachi, Naoki</creator><creator>Suzuki, Hiroyuki</creator><creator>Sakai, Miwa</creator><creator>Kajiwara, Akira</creator><creator>Itano, Satoshi</creator><creator>Tanaka, Masatoshi</creator><creator>Yamaguchi, Taizo</creator><creator>Kuromatsu, Ryoko</creator><creator>Koga, Hironori</creator><creator>Torimura, Takuji</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3375-180X</orcidid><orcidid>https://orcid.org/0000-0002-4791-8885</orcidid><orcidid>https://orcid.org/0000-0001-5814-9543</orcidid><orcidid>https://orcid.org/0000-0002-2662-6779</orcidid><orcidid>https://orcid.org/0000-0003-2068-8386</orcidid><orcidid>https://orcid.org/0000-0003-2383-5038</orcidid></search><sort><creationdate>20210603</creationdate><title>Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice</title><author>Iwamoto, Hideki ; Shimose, Shigeo ; Noda, Yu ; Shirono, Tomotake ; Niizeki, Takashi ; Nakano, Masahito ; Okamura, Shusuke ; Kamachi, Naoki ; Suzuki, Hiroyuki ; Sakai, Miwa ; Kajiwara, Akira ; Itano, Satoshi ; Tanaka, Masatoshi ; Yamaguchi, Taizo ; Kuromatsu, Ryoko ; Koga, Hironori ; Torimura, Takuji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-69efd41ba3713a3c5ab7493f5ea71cd31dc43faaaa3b8a9ca3c46c817d8717d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adverse events</topic><topic>Bevacizumab</topic><topic>Bilirubin</topic><topic>Cancer therapies</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Disease control</topic><topic>Hepatocellular carcinoma</topic><topic>Hypertension</topic><topic>Liver cancer</topic><topic>Magnetic resonance imaging</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>Pharmaceuticals</topic><topic>Response rates</topic><topic>Statistical analysis</topic><topic>Tumors</topic><topic>Variance analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Iwamoto, Hideki</creatorcontrib><creatorcontrib>Shimose, Shigeo</creatorcontrib><creatorcontrib>Noda, Yu</creatorcontrib><creatorcontrib>Shirono, Tomotake</creatorcontrib><creatorcontrib>Niizeki, Takashi</creatorcontrib><creatorcontrib>Nakano, Masahito</creatorcontrib><creatorcontrib>Okamura, Shusuke</creatorcontrib><creatorcontrib>Kamachi, Naoki</creatorcontrib><creatorcontrib>Suzuki, Hiroyuki</creatorcontrib><creatorcontrib>Sakai, Miwa</creatorcontrib><creatorcontrib>Kajiwara, Akira</creatorcontrib><creatorcontrib>Itano, Satoshi</creatorcontrib><creatorcontrib>Tanaka, Masatoshi</creatorcontrib><creatorcontrib>Yamaguchi, Taizo</creatorcontrib><creatorcontrib>Kuromatsu, Ryoko</creatorcontrib><creatorcontrib>Koga, Hironori</creatorcontrib><creatorcontrib>Torimura, Takuji</creatorcontrib><creatorcontrib>on behalf of The Kurume Liver Cancer Study Group of Japan</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Iwamoto, Hideki</au><au>Shimose, Shigeo</au><au>Noda, Yu</au><au>Shirono, Tomotake</au><au>Niizeki, Takashi</au><au>Nakano, Masahito</au><au>Okamura, Shusuke</au><au>Kamachi, Naoki</au><au>Suzuki, Hiroyuki</au><au>Sakai, Miwa</au><au>Kajiwara, Akira</au><au>Itano, Satoshi</au><au>Tanaka, Masatoshi</au><au>Yamaguchi, Taizo</au><au>Kuromatsu, Ryoko</au><au>Koga, Hironori</au><au>Torimura, Takuji</au><aucorp>on behalf of The Kurume Liver Cancer Study Group of Japan</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice</atitle><jtitle>Cancers</jtitle><date>2021-06-03</date><risdate>2021</risdate><volume>13</volume><issue>11</issue><spage>2786</spage><pages>2786-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Background: Atezolizumab plus bevacizumab was approved for patients with hepatocellular carcinoma (HCC). Although clinical trials have revealed its efficacy, the outcomes in the real-world clinical practice are unclear. We retrospectively evaluated the efficacy and safety of atezolizumab plus bevacizumab for HCC. Materials and Methods: This is a multicenter study conducted between November 2020 and March 2021. Among the 61 patients, 51 were assessed for progression-free survival (PFS), therapeutic response, and adverse events (AEs). Results: The median PFS was 5.4 months. The objective response rate (ORR) was 35.3%. The disease control rate (DCR) was 86.3%. The incidence rates of AEs at any grade and grade >3 were 98.0% and 29.4%, respectively. The most frequent AE at any grade and grade >3 was hepatic disorder. In patients with a previous history of molecular targeted agent (MTA) or the degree of albumin-bilirubin (ALBI) grade, there were no significant differences in the PFS, ORR, DCR, and incidence rates of AEs. Conclusion: The study demonstrated that atezolizumab plus bevacizumab was effective and safe for patients with HCC even in the real-world setting including patients with a previous MTA history or other than ALBI grade 1.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>34205099</pmid><doi>10.3390/cancers13112786</doi><orcidid>https://orcid.org/0000-0002-3375-180X</orcidid><orcidid>https://orcid.org/0000-0002-4791-8885</orcidid><orcidid>https://orcid.org/0000-0001-5814-9543</orcidid><orcidid>https://orcid.org/0000-0002-2662-6779</orcidid><orcidid>https://orcid.org/0000-0003-2068-8386</orcidid><orcidid>https://orcid.org/0000-0003-2383-5038</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2021-06, Vol.13 (11), p.2786 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8199943 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Adverse events Bevacizumab Bilirubin Cancer therapies Clinical medicine Clinical trials Disease control Hepatocellular carcinoma Hypertension Liver cancer Magnetic resonance imaging Monoclonal antibodies Patients Pharmaceuticals Response rates Statistical analysis Tumors Variance analysis |
| title | Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T10%3A07%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Initial%20Experience%20of%20Atezolizumab%20Plus%20Bevacizumab%20for%20Unresectable%20Hepatocellular%20Carcinoma%20in%20Real-World%20Clinical%20Practice&rft.jtitle=Cancers&rft.au=Iwamoto,%20Hideki&rft.aucorp=on%20behalf%20of%20The%20Kurume%20Liver%20Cancer%20Study%20Group%20of%20Japan&rft.date=2021-06-03&rft.volume=13&rft.issue=11&rft.spage=2786&rft.pages=2786-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13112786&rft_dat=%3Cproquest_pubme%3E2539606086%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2539606086&rft_id=info:pmid/34205099&rfr_iscdi=true |